@article{MTMT:33134263,
	title = {Hosszú távú antilipidaemiás kezelés diabéteszben - SiRNS- alapú terápia?},
	url = {https://m2.mtmt.hu/api/publication/33134263},
	author = {Karádi, István},
	journal-iso = {METABOLIZMUS},
	journal = {METABOLIZMUS},
	volume = {20},
	unique-id = {33134263},
	issn = {1589-7311},
	year = {2022},
	pages = {6-9},
	orcid-numbers = {Karádi, István/0000-0002-8253-2654}
}

@article{MTMT:33134262,
	title = {Hipertónia és hypercholesterinaemia szinergizmusa},
	url = {https://m2.mtmt.hu/api/publication/33134262},
	author = {Karádi, István},
	journal-iso = {HÁZIORVOS TOVÁBBKÉPZŐ SZEMLE},
	journal = {HÁZIORVOS TOVÁBBKÉPZŐ SZEMLE},
	volume = {27},
	unique-id = {33134262},
	issn = {1219-8641},
	year = {2022},
	pages = {140-143},
	orcid-numbers = {Karádi, István/0000-0002-8253-2654}
}

@article{MTMT:33134270,
	title = {A lipidterápia újdonságai a VIII: Magyar Kardiovaszkuláris Konszenzus Konferencia ajánlásai nyomán},
	url = {https://m2.mtmt.hu/api/publication/33134270},
	author = {Karádi, István},
	journal-iso = {METABOLIZMUS},
	journal = {METABOLIZMUS},
	volume = {19},
	unique-id = {33134270},
	issn = {1589-7311},
	year = {2021},
	pages = {13-16},
	orcid-numbers = {Karádi, István/0000-0002-8253-2654}
}

@article{MTMT:33134269,
	title = {A lipidterápia újdonságai a VIII. Magyar Kardiovaszkuláris Konszenzus Konferencia ajánlásai nyomán},
	url = {https://m2.mtmt.hu/api/publication/33134269},
	author = {Karádi, István},
	journal-iso = {GYÓGYSZERÉSZ TOVÁBBKÉPZÉS},
	journal = {GYÓGYSZERÉSZ TOVÁBBKÉPZÉS},
	volume = {15},
	unique-id = {33134269},
	issn = {1788-9049},
	year = {2021},
	pages = {153-155},
	orcid-numbers = {Karádi, István/0000-0002-8253-2654}
}

@article{MTMT:33134268,
	title = {A lipidajánlást befolyásoló legújabb tanulmányok},
	url = {https://m2.mtmt.hu/api/publication/33134268},
	author = {Paragh, György and Karádi, István},
	journal-iso = {HÁZIORVOS TOVÁBBKÉPZŐ SZEMLE},
	journal = {HÁZIORVOS TOVÁBBKÉPZŐ SZEMLE},
	volume = {26},
	unique-id = {33134268},
	issn = {1219-8641},
	year = {2021},
	pages = {165-171},
	orcid-numbers = {Karádi, István/0000-0002-8253-2654}
}

@article{MTMT:33134266,
	title = {A lipidterápia újdonságai a VIII. Magyar Kardiovaszkuláris Konszenzus Konferencia ajánlásai nyomán},
	url = {https://m2.mtmt.hu/api/publication/33134266},
	author = {Karádi, István},
	journal-iso = {HÁZIORVOS TOVÁBBKÉPZŐ SZEMLE},
	journal = {HÁZIORVOS TOVÁBBKÉPZŐ SZEMLE},
	volume = {26},
	unique-id = {33134266},
	issn = {1219-8641},
	year = {2021},
	pages = {239-242},
	orcid-numbers = {Karádi, István/0000-0002-8253-2654}
}

@article{MTMT:33134264,
	title = {A lipidajánlást befolyásoló legújabb tanulmányok},
	url = {https://m2.mtmt.hu/api/publication/33134264},
	author = {Paragh, György and Karádi, István},
	journal-iso = {METABOLIZMUS},
	journal = {METABOLIZMUS},
	volume = {19},
	unique-id = {33134264},
	issn = {1589-7311},
	year = {2021},
	pages = {27-33},
	orcid-numbers = {Karádi, István/0000-0002-8253-2654}
}

@article{MTMT:32707348,
	title = {Új szemlélet a lipoprotein(a) fokozott plazmaszintjének kezelésében},
	url = {https://m2.mtmt.hu/api/publication/32707348},
	author = {Karádi, István},
	doi = {10.33616/LAM.31.037},
	journal-iso = {LEGE ART MED},
	journal = {LEGE ARTIS MEDICINAE},
	volume = {31},
	unique-id = {32707348},
	issn = {0866-4811},
	abstract = {A lipoprotein(a) genetikailag meghatározott, az LDL molekuláris szerkezetéhez ha­sonló lipoproteinfrakció, amelynek fokozott az atherogenitasa, és az athero­scle­ro­ticus ere­detű érbetegségek független kockázati tényezője. Plazmakoncentrációját kör­nyezeti té­nyezők (táplálkozás, életmód) nem befolyásolják, ezért a primer és szekunder cardiovascularis prevencióban el­sősorban a gyógyszeres terápia került előtérbe. A széleskörűen alkalmazott lipidcsökkentők nem befolyásolják a lipopro­tein(a) plazmaszintjét. A közelmúltban proprotein konvertáz szubtilizin-kexin-9 (PCSK-9) elleni monoklonális antitestek (evolocumab és alirocumab), valamint az siRNS alapú inclisiran, de különösen az LPA mRNS-t megcélzó antisense oligonukleotid, a pelacarsen klinikai alkalmazása so­rán jelentős lipoprotein(a)-csökkentő ha­tást észleltek. Az atheroscleroticus eredetű vascularis betegségek mellett a kalcifikáló aor­tabillentyű-stenosis patogenezisében is meg­­határozó szerepet játszik a lipoprotein(a). A fenti biológiai terápiák alkalmazása eb­ben a kórképben is reményteljes.},
	year = {2021},
	eissn = {2063-4161},
	pages = {503-509},
	orcid-numbers = {Karádi, István/0000-0002-8253-2654}
}

@article{MTMT:32351742,
	title = {A pharmacokinetics-based approach to the monitoring of patient adherence to atorvastatin therapy},
	url = {https://m2.mtmt.hu/api/publication/32351742},
	author = {Karvaly, Gellért Balázs and Karádi, István and Vincze, István and Neely, M.N. and Trojnár, Eszter and Prohászka, Zoltán and Imreh, Éva and Vásárhelyi, Barna and Zsáry, András},
	doi = {10.1002/prp2.856},
	journal-iso = {PHARMACOL RES PERSPECT},
	journal = {PHARMACOLOGY RESEARCH AND PERSPECTIVES},
	volume = {9},
	unique-id = {32351742},
	issn = {2052-1707},
	abstract = {The inadequate adherence of patients whose hyperlipidemia is treated with atorvastatin (ATR) to medical instructions presents a serious health risk. Our aim was to develop a flexible approach based on therapeutic drug monitoring (TDM), nonparametric population pharmacokinetic modeling, and Monte Carlo simulation to differentiate adherent patients from partially and nonadherent individuals in a nonrandomized, unicentric, observational study. Sixty-five subjects were enrolled. Nonparametric, mixed-effect population pharmacokinetic models of the sums of atorvastatin and atorvastatin lactone concentrations (ATR+ATRL) and of the concentrations of the acid and lactone forms of ATR and its 2- and 4-hydroxylated pharmacologically active metabolites (ATR+MET) were elaborated by including the TDM results obtained in 128 samples collected from thirty-nine subjects. Monte Carlo simulation was performed based on the elaborated models to establish the probabilities of attaining a specific ATR+ATRL or ATR+MET concentration in the range of 0.002-10 nmol (mg dose)-1 L-1 at 1-24 h postdose by adherent, partially adherent, and nonadherent patients. The results of the simulations were processed to allow the estimation of the adherence of further 26 subjects who were phlebotomized at sampling times of 2-20 h postdose by calculating the probabilities of attaining the ATR+ATRL and ATR+MET concentrations measured in these subjects in adherent, partially adherent, and nonadherent individuals. The best predictive values of the estimates of adherence could be obtained with sampling at early sampling times. 61.54% and 38.46% of subjects in the adherence testing set were estimated to be fully and partially adherent, respectively, while in all cases the probability of nonadherence was extremely low. The evaluation of patient adherence to ATR therapy based on pharmacokinetic modeling and Monte Carlo simulation has important advantages over the collection of trough samples and the use of therapeutic ranges. © 2021 The Authors. Pharmacology Research & Perspectives published by British Pharmacological Society and American Society for Pharmacology and Experimental Therapeutics and John Wiley & Sons Ltd.},
	keywords = {PHARMACOKINETICS; metabolism; ATORVASTATIN; Adherence; therapeutic drug monitoring; nonparametric pharmacokinetic model},
	year = {2021},
	eissn = {2052-1707},
	orcid-numbers = {Karvaly, Gellért Balázs/0000-0003-2468-5633; Karádi, István/0000-0002-8253-2654; Vincze, István/0000-0002-6843-7159; Trojnár, Eszter/0000-0002-3266-2477; Prohászka, Zoltán/0000-0003-1761-7982; Imreh, Éva/0000-0001-5343-9517; Vásárhelyi, Barna/0000-0003-0055-7346; Zsáry, András/0000-0002-4994-1448}
}

@article{MTMT:31966426,
	title = {Sensitive, High-Throughput Liquid Chromatography-Tandem Mass Spectrometry Analysis of Atorvastatin and Its Pharmacologically Active Metabolites in Serum for Supporting Precision Pharmacotherapy},
	url = {https://m2.mtmt.hu/api/publication/31966426},
	author = {Karvaly, Gellért Balázs and Vincze, István and Karádi, István and Vásárhelyi, Barna and Zsáry, András},
	doi = {10.3390/molecules26051324},
	journal-iso = {MOLECULES},
	journal = {MOLECULES},
	volume = {26},
	unique-id = {31966426},
	issn = {1420-3049},
	abstract = {The antihyerlipidemic drug atorvastatin (ATR) is used worldwide as part of the strategy to prevent cardiovascular events. The high prevalence of patient nonadherence remains an important challenge which could be addressed efficiently by precision pharmacotherapy based on therapeutic drug monitoring (TDM). ATR is metabolized to pharmacologically active metabolites, and evidence shows that the sums of ATR acid and lactone form concentrations (ATR + ATRL), or of ATR and hydroxylated metabolites (ATR + MET) should be assayed. A method is presented for the analysis of these substances in serum. Method validation included the estimation of the quantitative relationship between the concentrations and the standard deviations (SD), which supports the optimal incorporation of TDM results into nonparametric pharmacokinetic models. The concentrations of the analytes were evaluated in human subjects receiving ATR. The method's performance improved by taking the sums of acid and lactone concentrations into account. The concentration-SD relationship was linear, and we recommend applying Theil's regression for estimating the assay error. All analytes could be detected by 2 h post dose in the samples of human subjects. The changes in metabolite/parent drug concentration ratios in time depended on the dose. The method is suitable for the TDM of ATR with a focus on precision pharmacotherapy.},
	keywords = {PHARMACOKINETICS; ATORVASTATIN; therapeutic drug monitoring; Biochemistry & Molecular Biology; hydroxyatorvastatin; atorvastatin lactone; individualized drug therapy},
	year = {2021},
	eissn = {1420-3049},
	orcid-numbers = {Karvaly, Gellért Balázs/0000-0003-2468-5633; Vincze, István/0000-0002-6843-7159; Karádi, István/0000-0002-8253-2654; Vásárhelyi, Barna/0000-0003-0055-7346; Zsáry, András/0000-0002-4994-1448}
}